Published in Neuron Glia Biol on May 01, 2004
Diffuse glioma growth: a guerilla war. Acta Neuropathol (2007) 2.11
Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget (2011) 1.39
Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin Cancer Res (2007) 1.21
An extensive invasive intracranial human glioblastoma xenograft model: role of high level matrix metalloproteinase 9. Am J Pathol (2010) 1.16
Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells. Cancer Gene Ther (2010) 1.14
MicroRNA 203 Modulates Glioma Cell Migration via Robo1/ERK/MMP-9 Signaling. Genes Cancer (2013) 1.12
Downregulation of uPAR and cathepsin B induces apoptosis via regulation of Bcl-2 and Bax and inhibition of the PI3K/Akt pathway in gliomas. PLoS One (2010) 1.08
Interleukin-1 regulates the expression of sphingosine kinase 1 in glioblastoma cells. J Biol Chem (2008) 1.08
Cell surface remodeling by plasmin: a new function for an old enzyme. J Biomed Biotechnol (2012) 1.04
RNA interference-mediated simultaneous down-regulation of urokinase-type plasminogen activator receptor and cathepsin B induces caspase-8-mediated apoptosis in SNB19 human glioma cells. Mol Cancer Ther (2006) 1.03
Suppression of uPAR retards radiation-induced invasion and migration mediated by integrin β1/FAK signaling in medulloblastoma. PLoS One (2010) 1.02
Reduction of metastatic and angiogenic potency of malignant cancer by Eupatorium fortunei via suppression of MMP-9 activity and VEGF production. Sci Rep (2014) 1.01
Tissue inhibitor of metalloproteinase 3 suppresses tumor angiogenesis in matrix metalloproteinase 2-down-regulated lung cancer. Cancer Res (2008) 0.99
Concepts in in vivo siRNA delivery for cancer therapy. J Cell Physiol (2009) 0.98
Co-depletion of cathepsin B and uPAR induces G0/G1 arrest in glioma via FOXO3a mediated p27 upregulation. PLoS One (2010) 0.98
Glioma angiogenesis: Towards novel RNA therapeutics. Cell Adh Migr (2009) 0.98
The role of MMP-9 in the anti-angiogenic effect of secreted protein acidic and rich in cysteine. Br J Cancer (2010) 0.97
RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis. Int J Oncol (2007) 0.94
Therapeutic potential of siRNA-mediated targeting of urokinase plasminogen activator, its receptor, and matrix metalloproteinases. Methods Mol Biol (2009) 0.93
High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis. World J Gastroenterol (2012) 0.93
Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer. Mol Biol Cell (2013) 0.90
Intraocular matrix metalloproteinase 2 and 9 in patients with diabetes mellitus with and without diabetic retinopathy. Arch Med Sci (2010) 0.90
Diffusion-weighted magnetic resonance imaging reversal by gene knockdown of matrix metalloproteinase-9 activities in live animal brains. J Neurosci (2009) 0.90
Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors. Oncogene (2010) 0.89
Aqueous extract of Bambusae Caulis in Taeniam inhibits PMA-induced tumor cell invasion and pulmonary metastasis: suppression of NF-κB activation through ROS signaling. PLoS One (2013) 0.88
Transfection with anti-p65 intrabody suppresses invasion and angiogenesis in glioma cells by blocking nuclear factor-kappaB transcriptional activity. Clin Cancer Res (2007) 0.86
uPAR and cathepsin B inhibition enhanced radiation-induced apoptosis in gliomainitiating cells. Neuro Oncol (2012) 0.86
Nano to micro delivery systems: targeting angiogenesis in brain tumors. J Angiogenes Res (2010) 0.82
uPAR and cathepsin B downregulation induces apoptosis by targeting calcineurin A to BAD via Bcl-2 in glioma. J Neurooncol (2011) 0.81
Simultaneous knockdown of uPA and MMP9 can reduce breast cancer progression by increasing cell-cell adhesion and modulating EMT genes. Sci Rep (2016) 0.81
Radiation-inducible silencing of uPA and uPAR in vitro and in vivo in meningioma. Int J Oncol (2010) 0.80
Oncogenic role of p53 is suppressed by si-RNA bicistronic construct of uPA, uPAR and cathepsin-B in meningiomas both in vitro and in vivo. Int J Oncol (2011) 0.79
Tristetraprolin inhibits the growth of human glioma cells through downregulation of urokinase plasminogen activator/urokinase plasminogen activator receptor mRNAs. Mol Cells (2014) 0.78
In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models. Gene Ther (2014) 0.77
EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment. Int J Mol Sci (2017) 0.76
A novel peptide blocking cancer cell invasion by structure-based drug design. Biomed Rep (2017) 0.75
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 57.23
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol (2000) 13.29
Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev (2000) 8.24
MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell (2000) 8.00
Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci U S A (2001) 7.12
U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells. Nat Biotechnol (2002) 6.66
The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer (1997) 5.01
RNA interference: listening to the sound of silence. Nat Struct Biol (2001) 4.05
Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol (2001) 3.32
Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem (1991) 2.61
Glioma invasion in the central nervous system. Neurosurgery (1996) 2.60
Role of the double-stranded RNA-activated protein kinase (PKR) in cell regulation. Biochem Soc Trans (1997) 2.15
Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem (1995) 2.06
Germline transmission of RNAi in mice. Nat Struct Biol (2003) 2.05
Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene (2004) 1.91
PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation. Cancer Res (2002) 1.88
Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci U S A (1993) 1.82
Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem (1998) 1.78
Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun (2002) 1.75
Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer (1999) 1.71
Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J Cell Biol (1994) 1.65
Generation and characterization of urokinase receptor-deficient mice. J Clin Invest (1996) 1.54
Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor. J Biol Chem (2002) 1.50
Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res (2000) 1.46
Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res (1996) 1.45
Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res (1999) 1.38
Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene (2003) 1.36
Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res (2002) 1.33
VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J (2003) 1.32
Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. Cancer Res (1998) 1.28
Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res (2000) 1.27
Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol (1997) 1.27
Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res (1996) 1.27
Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis (1996) 1.27
Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene (2001) 1.26
Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res (1991) 1.22
The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann N Y Acad Sci (1992) 1.19
The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J Biol Chem (1998) 1.17
Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J Neurosurg (1995) 1.17
Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. Blood (1997) 1.17
Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res (1994) 1.16
Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors. Cancer Res (1993) 1.16
Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am J Pathol (1998) 1.15
Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion. Oncogene (2002) 1.15
Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res (2004) 1.14
Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res (1994) 1.13
Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene (2002) 1.12
Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther (1998) 1.10
Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin Exp Metastasis (1996) 1.09
Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction. Eur J Biochem (1998) 1.08
RNAi: gene-silencing in therapeutic intervention. Drug Discov Today (2002) 1.07
In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor. Oncogene (1997) 1.05
Expression of tissue inhibitors of metalloproteinases: negative regulators of human glioblastoma invasion in vivo. Clin Exp Metastasis (1995) 1.05
Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth. Cancer Res (1999) 1.04
Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma. Am J Pathol (1995) 1.03
Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth. Cancer Res (2003) 1.03
Migratory patterns of lac-z transfected human glioma cells in the rat brain. Int J Cancer (1995) 1.03
Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator. Oncogene (2002) 0.99
Roles of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in the signal transduction of basic fibroblast growth factor in endothelial cells during angiogenesis. Jpn J Cancer Res (1999) 0.97
Stable transfection of urokinase-type plasminogen activator antisense construct modulates invasion of human glioblastoma cells. Clin Cancer Res (2001) 0.97
Localization of gelatinase-A and gelatinase-B mRNA and protein in human gliomas. Neuro Oncol (2000) 0.96
Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Int J Cancer (1999) 0.95
Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors. Clin Exp Metastasis (1997) 0.94
The urokinase receptor. A cell surface, regulated chemokine. APMIS (1999) 0.93
Regulation of MMP-9 (type IV collagenase) production and invasiveness in gliomas by the extracellular signal-regulated kinase and jun amino-terminal kinase signaling cascades. Clin Exp Metastasis (2000) 0.93
High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread. FEBS Lett (2002) 0.92
Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J Natl Cancer Inst (2002) 0.90
Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. Breast Cancer Res Treat (1996) 0.88
The role of the plasminogen activation system in cancer. Semin Thromb Hemost (1999) 0.87
Extracellular matrix remodeling as a regulator of stromal-epithelial interactions during mammary gland development, involution and carcinogenesis. Braz J Med Biol Res (1996) 0.85
Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res (1999) 0.84
3-Amidinophenylalanine-based inhibitors of urokinase. Bioorg Med Chem Lett (1999) 0.83
Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride. Clin Exp Metastasis (1998) 0.83
Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428. Anticancer Res (1999) 0.82
Expression of multiple CD44 isoforms in the apical ectodermal ridge of the embryonic mouse limb. Dev Dyn (1996) 0.81
Transfection of an invasive human astrocytoma cell line with a TIMP-1 cDNA: modulation of astrocytoma invasive potential. J Neuropathol Exp Neurol (1996) 0.79
High-molecular-weight serum protein complexes differentially promote cell migration and the focal adhesion localization of the urokinase receptor in human glioma cells. Exp Cell Res (2000) 0.78
Urokinase plasminogen activator is necessary but not sufficient for prostate cancer cell invasion. Invasion Metastasis (1995) 0.77
Modulation of endothelial cell morphogenesis in vitro by MMP-9 during glial-endothelial cell interactions. Clin Exp Metastasis (2000) 0.76
Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: in vitro and in vivo studies of uptake, effects and toxicity. Biochem Biophys Res Commun (1996) 0.76
RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem (2005) 2.38
Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene (2004) 1.91
YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res (2006) 1.53
MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. Int J Cancer (2010) 1.48
Downregulation of uPA inhibits migration and PI3k/Akt signaling in glioblastoma cells. Oncogene (2003) 1.41
Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity. Oncotarget (2012) 1.40
The heidenhain variant of Creutzfeldt-Jakob disease--a case series. J Neuroophthalmol (2014) 1.40
Proteases and glioma angiogenesis. Brain Pathol (2005) 1.39
Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene (2003) 1.36
RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene (2004) 1.35
Down-regulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K/AKT pathway. Int J Oncol (2007) 1.34
Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol Cancer Ther (2005) 1.33
Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis. Cancer Res (2007) 1.29
MMP-2 siRNA inhibits radiation-enhanced invasiveness in glioma cells. PLoS One (2011) 1.27
RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer (2007) 1.23
Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin Cancer Res (2007) 1.21
Adenovirus-mediated small interfering RNA against matrix metalloproteinase-2 suppresses tumor growth and lung metastasis in mice. Mol Cancer Ther (2006) 1.20
Cathepsin B as a cancer target. Expert Opin Ther Targets (2013) 1.19
Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. Brain Pathol (2008) 1.18
siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells. Int J Oncol (2006) 1.16
Blockade of tumor growth due to matrix metalloproteinase-9 inhibition is mediated by sequential activation of beta1-integrin, ERK, and NF-kappaB. J Biol Chem (2007) 1.16
Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion. Oncogene (2002) 1.15
Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res (2004) 1.14
Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis. Carcinogenesis (2014) 1.14
Axonal remyelination by cord blood stem cells after spinal cord injury. J Neurotrauma (2007) 1.13
Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene (2002) 1.12
MicroRNA 203 Modulates Glioma Cell Migration via Robo1/ERK/MMP-9 Signaling. Genes Cancer (2013) 1.12
Neuroprotection by cord blood stem cells against glutamate-induced apoptosis is mediated by Akt pathway. Neurobiol Dis (2008) 1.11
Cord blood stem cells revert glioma stem cell EMT by down regulating transcriptional activation of Sox2 and Twist1. Oncotarget (2011) 1.09
Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis. Int J Oncol (2008) 1.08
Recombinant adeno-associated virus (rAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line. Int J Cancer (2005) 1.08
Downregulation of uPAR and cathepsin B induces apoptosis via regulation of Bcl-2 and Bax and inhibition of the PI3K/Akt pathway in gliomas. PLoS One (2010) 1.08
Local mechanical properties of white matter structures in the human brain. Neuroimage (2013) 1.07
SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA. Int J Oncol (2006) 1.06
Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway. PLoS One (2010) 1.05
Localization of uPAR and MMP-9 in lipid rafts is critical for migration, invasion and angiogenesis in human breast cancer cells. BMC Cancer (2010) 1.05
Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Res (2007) 1.05
Mesenchymal stem cells from rat bone marrow downregulate caspase-3-mediated apoptotic pathway after spinal cord injury in rats. Neurochem Res (2007) 1.05
Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis. Oncogene (2004) 1.05